*Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

• About the I-neb AAD
  System

•      Components

•      How the AAD System
       Works

•      Breathing Technique

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Cleaning the AAD System

Once-a-day cleaning

• Distilled water protects used meshes until end-of-day cleaning
• Durable carrying cases simplify taking Ventavis^® (iloprost) Inhalation Solution to work and on the road

Blue: carrying case for clean chamber lids with mesh	Orange: carrying case for used chamber lids with mesh

Carrying cases fit right into the daily routine

Starting the Day

Load blue case with clean, dry chamber lids with mesh.	Fill orange case with distilled water and close the lid.

Taking Ventavis

After you have placed Ventavis into the I-neb AAD medication chamber, remove a clean, dry chamber lid with mesh from the blue case. Place the chamber lid on top of the medication chamber, close the latch, and attach the mouthpiece.	Take your Ventavis treatment.	Remove the used chamber lid from on top of the medication chamber and place it in the orange case filled with distilled water.

End of day cleaning

At the end of the day, remove the day's used chamber lids from the orange carrying case and place them in the mesh wash basket.	Place mouthpiece, medication chamber, and drug guide in main wash basket.	Using only one drop of dishwashing liquid without bleach, fragrances, or antibacterial ingredients, wash in distilled water. Rinse in distilled water. Air dry for 2 hours before using again.

Why cleaning with distilled water is important

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information